Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2014 L.P. Mpm Sells 21,623 Shares of Stock

Posted by Stanley Muller on Aug 27th, 2026

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock in a transaction on Monday, August 24th. The shares were sold at an average price of $7.34, for a total value of $158,712.82. Following the sale, the insider directly owned 4,359,439 shares of the company’s stock, valued at approximately $31,998,282.26. This trade represents a 0.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

On Wednesday, August 26th, Bioventures 2014 L.P. Mpm sold 14,569 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total value of $102,857.14.
On Tuesday, August 25th, Bioventures 2014 L.P. Mpm sold 26,522 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.54, for a total value of $199,975.88.

Entrada Therapeutics Price Performance

Shares of TRDA opened at $7.00 on Thursday. The company’s fifty day moving average price is $7.08 and its 200-day moving average price is $9.36. The firm has a market capitalization of $272.58 million, a PE ratio of -1.77 and a beta of -0.26. Entrada Therapeutics, Inc. has a 1-year low of $5.02 and a 1-year high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. As a group, research analysts anticipate that Entrada Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Entrada Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Baker BROS. Advisors LP increased its position in shares of Entrada Therapeutics by 4.3% during the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after acquiring an additional 206,911 shares during the last quarter. 5AM Venture Management LLC acquired a new stake in Entrada Therapeutics during the 2nd quarter valued at approximately $29,854,949,000. BlackRock Inc. acquired a new stake in Entrada Therapeutics during the 2nd quarter valued at approximately $19,013,000. Wellington Management Group LLP increased its holdings in Entrada Therapeutics by 9.5% during the 4th quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after purchasing an additional 90,339 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in Entrada Therapeutics by 391.2% during the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after purchasing an additional 666,287 shares during the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TRDA has been the subject of a number of analyst reports. Roth Capital reissued a “buy” rating and set a $11.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings downgraded shares of Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. HC Wainwright cut shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Finally, Guggenheim dropped their target price on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Entrada Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $17.75.

Check Out Our Latest Analysis on TRDA

Entrada Therapeutics Company Profile

(Get Free Report)

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.